JP2012512158A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512158A5
JP2012512158A5 JP2011540809A JP2011540809A JP2012512158A5 JP 2012512158 A5 JP2012512158 A5 JP 2012512158A5 JP 2011540809 A JP2011540809 A JP 2011540809A JP 2011540809 A JP2011540809 A JP 2011540809A JP 2012512158 A5 JP2012512158 A5 JP 2012512158A5
Authority
JP
Japan
Prior art keywords
methyl
compound according
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011540809A
Other languages
English (en)
Japanese (ja)
Other versions
JP5509217B2 (ja
JP2012512158A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/067056 external-priority patent/WO2010074947A1/en
Publication of JP2012512158A publication Critical patent/JP2012512158A/ja
Publication of JP2012512158A5 publication Critical patent/JP2012512158A5/ja
Application granted granted Critical
Publication of JP5509217B2 publication Critical patent/JP5509217B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011540809A 2008-12-16 2009-12-08 アミノピラゾール化合物 Expired - Fee Related JP5509217B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16
US61/122,854 2008-12-16
PCT/US2009/067056 WO2010074947A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Publications (3)

Publication Number Publication Date
JP2012512158A JP2012512158A (ja) 2012-05-31
JP2012512158A5 true JP2012512158A5 (enExample) 2013-01-24
JP5509217B2 JP5509217B2 (ja) 2014-06-04

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540809A Expired - Fee Related JP5509217B2 (ja) 2008-12-16 2009-12-08 アミノピラゾール化合物

Country Status (38)

Country Link
US (2) US7897600B2 (enExample)
EP (1) EP2379557B1 (enExample)
JP (1) JP5509217B2 (enExample)
KR (1) KR101300458B1 (enExample)
CN (1) CN102232075B (enExample)
AR (1) AR074240A1 (enExample)
AU (1) AU2009330503B2 (enExample)
BR (1) BRPI0923048A2 (enExample)
CA (1) CA2744714C (enExample)
CL (1) CL2011001445A1 (enExample)
CO (1) CO6331442A2 (enExample)
CR (1) CR20110341A (enExample)
CY (1) CY1113637T1 (enExample)
DK (1) DK2379557T3 (enExample)
DO (1) DOP2011000190A (enExample)
EA (1) EA019554B1 (enExample)
EC (1) ECSP11011132A (enExample)
ES (1) ES2396617T3 (enExample)
HN (1) HN2011001697A (enExample)
HR (1) HRP20120918T1 (enExample)
IL (1) IL213065A0 (enExample)
JO (1) JO2833B1 (enExample)
MA (1) MA32900B1 (enExample)
MX (1) MX2011006441A (enExample)
MY (1) MY158691A (enExample)
NZ (1) NZ592641A (enExample)
PA (1) PA8851101A1 (enExample)
PE (1) PE20110549A1 (enExample)
PL (1) PL2379557T3 (enExample)
PT (1) PT2379557E (enExample)
SG (1) SG172202A1 (enExample)
SI (1) SI2379557T1 (enExample)
SV (1) SV2011003949A (enExample)
TN (1) TN2011000292A1 (enExample)
TW (1) TWI440640B (enExample)
UA (1) UA104743C2 (enExample)
WO (1) WO2010074947A1 (enExample)
ZA (1) ZA201103942B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
EP2683444A1 (en) * 2011-03-07 2014-01-15 Fondazione Telethon Tfeb phosphorylation inhibitors and uses thereof
RU2014101070A (ru) * 2011-06-15 2015-07-20 Лайф Энд Брэйн Гмбх Ингибирующие глиобластому соединения и их применение
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
AR101504A1 (es) 2014-08-11 2016-12-21 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
EP3179991B1 (en) 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
KR102611856B1 (ko) * 2016-11-17 2023-12-07 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 이미다조피리다진 조정제
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
BRPI0215050B8 (pt) 2001-12-21 2021-05-25 Anormed Inc compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem
EP1853602B1 (en) 2005-02-16 2010-07-14 AstraZeneca AB Chemical compounds
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
PT1899329E (pt) * 2005-07-01 2012-01-13 Irm Llc Derivados de benzimidazole substituídos por pirimidina como inibidores de proteína quinase
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2007044426A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US7776865B2 (en) * 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
JP2010508315A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
WO2008143674A1 (en) 2007-05-23 2008-11-27 Pharmacopeia, Inc. Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Similar Documents

Publication Publication Date Title
JP2012512158A5 (enExample)
HRP20120918T1 (hr) Aminopirazolski spoj
HRP20161674T1 (hr) 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE
RU2018102080A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2014511893A5 (enExample)
JP2014521735A5 (enExample)
IL196854A (en) Indole compounds and their appropriate pharmaceutical salts and their use in the preparation of @ drugs
WO2009088414A3 (en) Oral pharmaceutical dosage forms
EP2179291A4 (en) ARZNEISTOFFAUSWAHL FÜR LUNGSKREBSTHERAPIE USING ARRAYS ON ANTIBODY BASIS
JP2010536849A5 (enExample)
EP2220093A4 (en) METHOD FOR THE PRODUCTION OF SITAGLIPTIN AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2012524089A5 (enExample)
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
IL196470A0 (en) Antagonist antibody against epha2 for the treatment of cancer
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2009006613A (es) Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
MY191934A (en) Macrocyclic compounds as trk kinase inhibitors
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
ZA200703989B (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы